Scarica l'app Stockscreener
1.67
1.18%
-0.02
Dopo l'orario di chiusura:
1.65
-0.02
-1.20%
Longeveron Inc Borsa (LGVN) Ultime notizie
What analysts say about Longeveron Inc. stockPowerful market insights - PrintWeekIndia
What risks could impact Longeveron Inc. stock performanceMarket-leading capital gains - jammulinksnews.com
Longeveron Inc. Stock Analysis and ForecastFree Wealth Management Insights - Autocar Professional
Is Longeveron Inc. a good long term investmentExplosive earnings growth - jammulinksnews.com
How Longeveron Inc. stock performs during market volatilityIntraday Trade Ideas - Newser
What drives Longeveron Inc. stock priceHigh-impact investment strategies - jammulinksnews.com
Published on: 2025-07-22 07:30:15 - Autocar Professional
Longeveron licenses patent for stem cell technology from University of Miami - TipRanks
Longeveron licenses stem cell patent for heart disease treatment - Investing.com
Longeveron licenses stem cell patent for heart disease treatment By Investing.com - Investing.com Nigeria
Longeveron Licenses US Patent for Advanced Cardiomyogenic Cell Technology from University of Miami - Nasdaq
Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease - The Manila Times
Revolutionary Heart Disease Breakthrough: Longeveron Licenses Safer Cardiac Stem Cell Technology - Stock Titan
What makes Longeveron Inc. stock price move sharplyFree Exclusive Stock Market Insights - Newser
Why Longeveron Inc. stock attracts strong analyst attentionLong Term Safe Yield Focus - Newser
Longeveron (LGVN) gets FDA nod to start Phase 2 laromestrocel trial | PLUG SEC FilingForm 424B7 - Stock Titan
Longeveron receives FDA approval for pediatric heart therapy IND By Investing.com - Investing.com South Africa
Longeveron®? Announces U.S. FDA Approval of IND Application for A Phase 2 Pivotal Registration Study Evaluating Laromestrocel as A Treatment of Pediatric Dilated Cardiomyopathy - MarketScreener
Longeveron® announces U.S. FDA approval of IND application - MarketScreener
Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM) - The Manila Times
Longeveron receives FDA approval for pediatric heart therapy IND - Investing.com Australia
Longeveron stock soars after FDA approves IND for heart failure treatment - Investing.com Nigeria
Longeveron stock soars after FDA approves IND for heart failure treatment By Investing.com - Investing.com South Africa
Longeveron Inc. Receives FDA Approval for IND Application to Advance Clinical Trial of Stem Cell Therapy for Pediatric Dilated Cardiomyopathy - Nasdaq
Breakthrough: FDA Fast-Tracks New Stem Cell Therapy for Fatal Children's Heart Condition - Stock Titan
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):